|
|
Diabetes Drug Delivery Methods - Market and TechnologiesPublished by: Frost & Sullivan Published: Jun. 9, 2006 - 193 Pages Table of Contents
1. Executive Summary of the Diabetes Drug Delivery Methods-Market and Technologies. 1. Market Overview 2. Introduction 1. Research Methodology 1. Research Methodology for the Diabetes Drug Delivery Methods- Market and Technologies 2. Exchange Rates 1. Currency Conversion 3. History Of Insulin 1. History 3. Overview of Insulin 1. Insulins 1. Animal Insulins 2. Semi-synthetic and Genetically Engineered Insulins 4. Insulin Delivery 1. Current Delivery Devices - Technology 1. Insulin Syringes 2. Insulin Jet Injectors 3. Insulin Pumps 4. Insulin Pens 2. Current Delivery Devices - Market Engineering Research 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers for Insulin Syringes Market 4. Market Restraints for Insulin Syringes Market 5. Market Drivers for Insulin Pumps and Jet Injectors Market 6. Market Restraints for Insulin Pumps and Jet Injectors Market 7. Market Drivers for Insulin Pens Market 8. Market Restraints for Insulin Pens Market 9. Competitive Structure 10. Market Share Analysis 11. Revenue Forecasts 5. Novel Insulin Delivery Devices 1. Introduction 1. Advancements in Diabetes Therapy 2. Drug Delivery - Future Technologies 1. Inhaled Insulin 2. Oral Insulin 3. Transdermal Insulin 4. Nanotechnology 5. Diabetes Vaccine 6. Gene Therapy 6. Market Engineering Research for Inhaled Insulins 1. Industry Challenges 1. Strategic Factors 2. Europe 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Competitive Structure 6. Revenue Forecasts 3. The United Kingdom 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 4. Germany 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 5. France 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 6. Spain 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 7. Italy 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 8. Scandinavia 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 9. Benelux 1. Market Overview 2. Market Engineering Measurements 3. Market Drivers 4. Market Restraints 5. Revenue Forecasts 7. Strategic Recommendations for the European Inhaled Insulin Market 1. Market Engineering Strategic Recommendations 1. Market Engineering Strategy 8. Frost & Sullivan Awards 1. 2006 Frost & Sullivan Awards 1. Frost & Sullivan Awards for the European Diabetes Drug Delivery Market 2. Technology Innovation Award 3. Product Line Strategy Award 4. Market Leadership Award 9. Database of Key Industry Participants 1. Key Industry Participants 1. Major Participants 10. Appendix 1. Decision Support Database 1. Diabetes Incidence 2. Diabetes Prevalence 3. Diabetes Prevalence Percent 4. Obesity Prevalence 5. Total Healthcare Expenditure List of Figures Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 AbstractResearch OverviewThis Frost & Sullivan research service titled Drug Delivery for Diabetes-Market and Technologies provides an overview of advancements in drug delivery technologies in diabetes. It also provides a description of the revenues generated by present insulin delivery methods along with a complete analysis of key market drivers, restraints and trends prevailing in the European market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: insulin syringes, insulin pens, insulin pumps and inhaled insulin. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
The following technologies are covered in this research:
Non-invasive Insulin Delivery to Significantly Improve Diabetes Management The growing demand for non-invasive delivery of insulin, particularly inhaled insulin, is leading to increased focus on the diabetes drug delivery market in Europe. Moreover, due to the irregularity exhibited by a significant number of patients in following insulin therapy, companies are pursuing insulin delivery methods that involve reduced pain, thereby facilitating compliance with the therapy. While various non-invasive delivery methods such as oral insulin, transdermal delivery and nanotechnology are still under research, the overall drug discovery market is anticipated to exhibit strong growth. "For diabetic patients using insulin injections, who are faced with issues such as infections, improper administration of insulin and uncontrolled blood glucose, alternate insulin delivery methods are likely to offer tremendous benefits," remarks the analyst of this research service. In addition, with the ability of inhaled insulin to offer glycaemic control comparable to insulin injections, such advantages are likely to promote market growth. Competitive Pricing Key to Market Growth Despite the potential of the market, long-term safety and efficacy of pulmonary delivery of insulin are factors expected to pose a challenge to market growth. While the Food and Drug Administration (FDA) as well as the European Medical Evaluation Agency (EMEA) have approved Exubera (the first inhaled insulin to enter the market), occurrences of pulmonary fibrosis during clinical trials are causing concerns about its safety. Hence, pharmaceutical companies involved in the research of inhaled insulin devices will need to focus on long-term safety of emerging insulin delivery methods. At the same time, novel insulin delivery methods, such as transdermal insulin delivery, are anticipated to gain prominence across Europe "The reimbursement of inhaled insulin, which relies on its cost effectiveness as well as patient compliance, is likely to be hampered by its high prices," says the analyst. "Hence, the advantages of convenience, safety and accuracy of inhaled insulin in comparison to conventional insulin, will need to be proved to justify the high costs." Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||